Sageworth Trust’s Teva Pharmaceuticals TEVA Stock Holding History

Sageworth Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-5,666	Closed	-$326K	–	76
2014 Q4	$326K	Buy	+5,666	New	+$316K	0.1%	71

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Sageworth Trust's TEVA Position: Q1 2015 in Review

Sageworth Trust sold out of Teva Pharmaceuticals (TEVA) in Q1 2015, closing a stake of 5,666 shares — an estimated $326K sold.

Sageworth Trust first reported a position in TEVA in Q4 2014 and held it in 1 quarter. The position peaked at $326K in Q4 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

Sageworth Trust reported no remaining Teva Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Sageworth Trust sold 5,666 Teva Pharmaceuticals shares in Q1 2015, an estimated $326K.
Sageworth Trust first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 1 quarter.
Sageworth Trust's Teva Pharmaceuticals position peaked at $326K in Q4 2014.
821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on Sageworth Trust's 13F filing for Q1 2015, filed 1 May 2015.